Every month, millions of Americans face an impossible choice: pay rent or buy insulin. This isn't hyperbole—it's the stark reality of a healthcare system that has transformed a century-old medication, discovered by researchers who refused to patent it because they believed it belonged to humanity, into one of the most expensive drugs in the world.
Insulin, essential for the survival of approximately 8.4 million Americans with diabetes, costs an average of $300 per vial in the United States. The same vial sells for $40 in neighboring Canada and as little as $7 in countries like India. This isn't a story about research and development costs or market innovation—it's about how pharmaceutical corporations have weaponized patent law and regulatory capture to hold diabetic Americans hostage.
The Monopoly Machine
Three companies—Eli Lilly, Novo Nordisk, and Sanofi—control approximately 90% of the global insulin market. This oligopoly didn't emerge through superior innovation or natural market forces. Instead, these corporations have systematically gamed the patent system through a practice known as "evergreening," making minor modifications to insulin formulations to extend patent protections far beyond their intended lifespan.
The original insulin patent, filed by Frederick Banting and his colleagues in 1923, was sold to the University of Toronto for $1 because the discoverers believed no one should profit from a medication essential for survival. Today, that same medication—with minor tweaks that don't meaningfully improve patient outcomes—generates over $24 billion in annual revenue for pharmaceutical giants.
Eli Lilly provides perhaps the most egregious example of this exploitation. The company's Humalog insulin, launched in 1996 at $21 per vial, now costs over $300—a 1,400% price increase that far outpaces inflation, healthcare costs, or any reasonable measure of improved value. During this same period, Eli Lilly CEO David Ricks received $21.5 million in total compensation in 2023, while the company reported record profits of $5.2 billion.
The Production Lie
Pharmaceutical companies routinely justify insulin prices by citing manufacturing costs and research investments. This narrative crumbles under scrutiny. A comprehensive study published in BMJ Global Health found that insulin can be profitably manufactured for as little as $2.28 per vial, including a reasonable profit margin.
The research and development argument is equally hollow. Most insulin innovations build on decades-old discoveries funded by taxpayer-supported research at public universities. The National Institutes of Health has invested billions in diabetes research, yet American taxpayers see none of the returns when pharmaceutical companies price the resulting medications beyond reach.
Meanwhile, these same companies spend more on executive compensation and stock buybacks than on research and development. Eli Lilly spent $5.2 billion on share repurchases in 2023—money that could have provided free insulin to every diabetic American for nearly two years.
The Human Toll of Corporate Greed
Behind these statistics are real people making impossible choices. The American Diabetes Association estimates that one in four diabetic Americans ration their insulin due to cost—a practice that can lead to diabetic ketoacidosis, coma, and death.
Alec Smith became a tragic symbol of this crisis when he died at age 26 after rationing insulin due to cost. After aging out of his mother's insurance plan, Smith couldn't afford the $1,300 monthly cost of his insulin and diabetes supplies. His death was entirely preventable—a direct result of a healthcare system that prioritizes pharmaceutical profits over human life.
Smith's story isn't unique. The advocacy group T1International has documented hundreds of similar cases, creating a growing memorial to Americans who died because they couldn't afford a medication that costs pennies to produce.
International Embarrassment
The contrast with other developed nations is stark and damning. In the United Kingdom, the National Health Service negotiates drug prices directly with manufacturers, keeping insulin costs low. France's healthcare system covers insulin completely for diabetic patients. Even in developing countries like Bangladesh, insulin is available at a fraction of U.S. prices.
This isn't because these countries lack robust pharmaceutical industries or intellectual property protections. It's because their governments refuse to allow essential medications to be held hostage by corporate greed.
The Regulatory Capture Problem
The Food and Drug Administration, theoretically responsible for protecting American consumers from pharmaceutical exploitation, has instead become a willing accomplice to industry price manipulation. The agency's complex approval process for biosimilar insulin products—generic alternatives that could introduce price competition—creates barriers that protect incumbent manufacturers.
While the FDA has approved several biosimilar insulin products in recent years, the process took decades longer than necessary, allowing the Big Three insulin manufacturers to extract billions in excess profits. This regulatory favoritism represents a massive transfer of wealth from sick Americans to pharmaceutical shareholders.
Medicare's Missed Opportunity
The Biden administration's Inflation Reduction Act included provisions allowing Medicare to negotiate prescription drug prices—a power that every other developed nation's healthcare system takes for granted. However, the legislation's impact on insulin prices has been limited, affecting only Medicare recipients while leaving millions of working-age Americans exposed to price gouging.
The $35 monthly insulin cap for Medicare beneficiaries, while helpful for seniors, highlights the arbitrary nature of drug pricing. If insulin can be profitably provided to Medicare patients for $35 monthly, why do working Americans pay ten times more for the same medication?
Corporate Welfare Disguised as Innovation
Pharmaceutical companies receive massive taxpayer subsidies through research grants, tax incentives, and patent protections, yet claim these benefits don't obligate them to provide affordable access to resulting medications. This represents corporate welfare on a massive scale—privatizing profits while socializing research costs and health consequences.
The industry's lobbying expenditures—over $4.7 billion annually—exceed the GDP of some nations and ensure continued political protection for this extractive business model. PhRMA, the industry's primary lobbying group, employs more lobbyists than there are members of Congress, guaranteeing that pharmaceutical interests are well-represented in every healthcare policy discussion.
Breaking the Cycle
Several policy solutions could immediately address the insulin crisis. Direct government manufacturing of generic insulin, similar to how the Department of Veterans Affairs produces some medications, could provide cost-effective alternatives. Compulsory licensing could break patent monopolies on essential medications when companies engage in price gouging.
California's CalRx initiative, which aims to produce generic insulin at cost, offers a model for state-level action. If successful, this program could force national price reductions and demonstrate that government can deliver essential medications more efficiently than private monopolies.
The Moral Reckoning
The insulin crisis represents a fundamental moral failure of American capitalism—a system that allows corporations to profit from human suffering while claiming the mantle of innovation and efficiency. When pharmaceutical executives receive multi-million-dollar bonuses while diabetic Americans die from rationing medication, the system has lost any claim to legitimacy.
This isn't about free markets or innovation—it's about organized theft enabled by regulatory capture and political corruption, and it's time Americans demanded better than a healthcare system that treats life-sustaining medications as luxury goods.
